Method for in situ determination of nucleic acid proximity

Patent metadata

Field	Value
Publication number	US-11279974-B2
Application number	US-201515532353-A
Country	US
Kind code	B2
Filing date	Dec 1, 2015
Priority date	Dec 1, 2014
Publication date	Mar 22, 2022
Grant date	Mar 22, 2022

Abstract

Disclosed is an in situ method for detecting spatial proximity relationships between nucleic acid sequences, such as DNA, in a cell. The method includes: providing a sample of one or more cells comprising nucleic acids; fragmenting the nucleic acids present in the cells that leaves 5′ overhanging ends; filling in the overhanging ends with at least one labeled nucleotide; joining the filled in end of the fragmented nucleic acids that are in close physical proximity to create one or more end joined nucleic acid fragments having a junction; isolating the one or more end joined nucleic acid fragments using the labeled nucleotide; and determining the sequence at the junction of the one or more end joined nucleic acid fragments.

First claim

We claim:

1. A method for altering one or more chromatin loops anchored on a loop anchor of one or more specific genomic regions of a chromosome in one or more cells of a cell type from a sample, wherein the sample is from an organ or a tissue or primary cells or cultured cells, said method comprising:
introducing one or more CRISPR/Cas systems into the one or more cells of the cell type from the sample, wherein the one or more CRISPR/Cas systems target a region within or around a pair of convergent CTCF motifs on one or more specific genomic regions of a chromosome in the one or more cells of the cell type, wherein the one or more specific genomic regions of the chromosome in the one or more cells of the cell type comprise one or more chromatin loops, wherein the one or more chromatin loops are identified using a chromosome conformation capture technology and are anchored on a loop anchor comprising the pair of convergent CTCF motifs on the one or more specific genomic regions of the chromosome in the one or more cells of the cell type, and wherein the one or more CRISPR/Cas systems are CRISPR/Cas RNA-guided DNA endonuclease systems,
wherein said introducing one or more CRISPR/Cas systems into the one or more cells of the cell type introduces a CTCF motif into the loop anchor of the one or more specific genomic regions of the chromosome in the one or more cells of the cell type or
wherein said introducing one or more CRISPR/Cas systems into the one or more cells of the cell type removes a CTCF motif from the pair of convergent CTCF motifs on the loop anchor of the one or more specific genomic regions of the chromosome in the one or more cells of the cell type,
whereby the one or more chromatin loops anchored on the loop anchor of the one or more specific genomic regions of the chromosome in the one or more cells of the cell type are altered.

2. The method of claim 1 , wherein the pair of convergent CTCF motifs comprises a consensus DNA sequence 5′-CCACNAGGTGGCAG-3′.

3. The method of claim 1 , wherein at least one base in the pair of convergent CTCF motifs is mutated.

4. The method of claim 1 , wherein the CTCF motif is introduced into the loop anchor of the one or more specific genomic regions of the chromosome in the one or more cells of the cell type in an inverted orientation.

5. The method of claim 4 , wherein a new chromatin loop is generated from the CTCF motif in the inverted orientation on the loop anchor.

6. The method of claim 1 , further comprising introducing two CTCF motifs in a convergent orientation into the loop anchor of the one or more specific genomic regions of the chromosome in the one or more cells of the cell type using one or more CRISPR/Cas systems targeting a region within or around the pair of convergent CTCF motifs on the one or more specific genomic regions of the chromosome in the one or more cells of the cell type such that a new chromatin loop is established.

7. The method of claim 1 , wherein the chromosome conformation capture technology is a Hi-C technique and generates a Hi-C heatmap, and pairs of loci that show significantly closer proximity with one another than with the loci lying between the pairs of loci in the Hi-C heatmap are peak loci and represent loop anchors.

8. The method of claim 7 , further comprising comparing the peak loci with gene expression data obtained from the one or more cells of the cell type, wherein the specific genomic regions are actively transcribed regions.

9. The method of claim 1 , wherein the one or more chromatin loops are involved in the regulation of the expression of a gene.

10. The method of claim 9 , wherein the one or more chromatin loops link a promoter and a regulatory element.

11. The method of claim 10 , wherein the regulatory element is an enhancer.

12. The method of claim 1 , wherein the one or more specific genomic regions is associated with a disease or condition.

13. The method of claim 12 , wherein the one or more cells of the cell type are associated with the disease or condition.

14. The method of claim 12 , wherein the one or more chromatin loops are associated with the regulation of a gene associated with the disease or condition.

15. The method of claim 1 , wherein said introducing the one or more CRISPR/Cas systems into the one or more cells of the cell type comprises delivering one or more vectors encoding the one or more CRISPR/Cas systems into the one or more cells of the cell type.

16. The method of claim 15 , wherein the vectors comprise a tissue-specific promoter.

17. The method of claim 1 , wherein said introducing the one or more CRISPR/Cas systems into the one or more cells of the cell type comprises delivering a cell-permeable reagent, a pyrrole-imidazole polyamide, into the one or more cells of the cell type.

18. The method of claim 1 , wherein the CRISPR/Cas systems comprise a nickase.

19. The method of claim 1 , wherein the CRISPR/Cas systems comprise one or more homology directed repair (HDR) templates.

20. The method of claim 1 , further comprising performing in situ Hi-C technique on said one or more cells of the cell type following said introducing the CRISPR/Cas systems into the one or more cells of the cell type such that an in situ Hi-C library is generated, optionally performing a HYbrid Capture technique after the in situ Hi-C library is generated.

21. The method of claim 20 , further comprising generating cell clones by culturing the one or more cells of the cell type after said introducing the one or more CRISPR/Cas systems into the one or more cells of the cell type and selecting cell clones having the altered chromatin loops.

22. The method of claim 21 , wherein the cell clones are screened for a specific phenotype.

23. The method of claim 1 , further comprising generating cell clones by culturing the one or more cells of the cell type after said introducing the CRISPR/Cas systems into the one or more cells of the cell type and selecting cell clones having a desired expression of one or more genes.

24. The method of claim 1 , wherein the one or more cells of the cell type are animal or plant cells.

25. The method of claim 1 , wherein the one or more chromatin loops are less than 2 Mb.

Assignees

• Broad Inst Inc
• Baylor College Medicine

Inventors

• Lieberman-Aiden Erez
• Rao Suhas
• Stamenova Elena
• Dudchenko Olga
• Lander Eric

Classifications

• C40B20/00

  Methods specially adapted for identifying library members · CPC title

• C12Q1/6827

  for detection of mutation or polymorphism · CPC title

• C12Q1/6869 Primary

  Methods for sequencing · CPC title

• C12Q2521/501

  Ligase · CPC title

• C12Q1/6806

  Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) · CPC title